Immunocore Holdings (IMCR) 주식 개요
Immunocore 홀딩스는 자회사와 함께 미국, 유럽 및 전 세계에서 암, 전염병 및 자가 면역 질환 환자를 위한 면역 조절 의약품의 개발 및 상용화에 종사하고 있습니다. 자세히 보기
IMCR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Immunocore Holdings plc 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$32.50 |
| 52주 최고가 | US$40.71 |
| 52주 최저가 | US$27.56 |
| 베타 | 0.73 |
| 1개월 변동 | 14.88% |
| 3개월 변동 | 1.69% |
| 1년 변동 | 0.28% |
| 3년 변동 | -49.80% |
| 5년 변동 | -16.69% |
| IPO 이후 변동 | -24.77% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 25
IMCR: Future Upside Will Rely On Melanoma Pipeline Trial Progress
Analysts maintained their $34.00 price target on Immunocore Holdings, citing only minor adjustments to assumptions for the discount rate, revenue growth and profit margins that did not materially change their overall view on the stock. What’s in the News for Immunocore Holdings Immunocore Holdings reported updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma, with brenetafusp monotherapy showing a 6‑month overall survival rate of 87% and a disease control rate of 52% in HLA‑A*02:01‑positive patients, according to presentations at the 2026 American Society of Clinical Oncology Annual Meeting.Seeking Alpha • Jun 24
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
Summary Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company with a validated commercial engine. KIMMTRAK's strong global sales, five-year survival data, and operating leverage underpin IMCR's ability to fund a broad pipeline without dilutive equity. Upcoming catalysts include pivotal readouts for tebentafusp and brenetafusp in melanoma, PRAME franchise expansion, and initial data in oncology, infectious disease, and autoimmune programs. IMCR trades at a 29% EV/Sales discount to sector median, with robust liquidity and multiple near-term clinical milestones supporting a favorable risk/reward profile. Read the full article on Seeking Alpha분석 기사 • Jun 18
Immunocore Holdings (IMCR) Stock Could Be 57.1% Undervalued After Annual Results
Immunocore Holdings (IMCR) continues to attract attention after reporting annual revenue of US$412.8 million and a net loss of US$27.6 million, which puts its current US$1.45b market value into sharper focus for investors. See our latest analysis for Immunocore Holdings. At a share price of US$28.59, Immunocore Holdings has seen its share price return decline 15.36% year to date, while the 1 year total shareholder return is down 9.81%. This points to cooling momentum after several years of...내러티브 업데이트 • Jun 06
IMCR: Future Upside Will Rely On High Risk Oncology Pipeline Progress
Narrative Update on Immunocore Holdings Analysts have reduced their price target for Immunocore Holdings to $33, down from $48. They cite a moderate total addressable market for Kimmtrak in uveal melanoma, expectations that sales are nearing peak, and a view that further upside depends on higher risk pipeline progress.Recent updates
내러티브 업데이트 • Jun 25
IMCR: Future Upside Will Rely On Melanoma Pipeline Trial Progress
Analysts maintained their $34.00 price target on Immunocore Holdings, citing only minor adjustments to assumptions for the discount rate, revenue growth and profit margins that did not materially change their overall view on the stock. What’s in the News for Immunocore Holdings Immunocore Holdings reported updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma, with brenetafusp monotherapy showing a 6‑month overall survival rate of 87% and a disease control rate of 52% in HLA‑A*02:01‑positive patients, according to presentations at the 2026 American Society of Clinical Oncology Annual Meeting.Seeking Alpha • Jun 24
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
Summary Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company with a validated commercial engine. KIMMTRAK's strong global sales, five-year survival data, and operating leverage underpin IMCR's ability to fund a broad pipeline without dilutive equity. Upcoming catalysts include pivotal readouts for tebentafusp and brenetafusp in melanoma, PRAME franchise expansion, and initial data in oncology, infectious disease, and autoimmune programs. IMCR trades at a 29% EV/Sales discount to sector median, with robust liquidity and multiple near-term clinical milestones supporting a favorable risk/reward profile. Read the full article on Seeking Alpha분석 기사 • Jun 18
Immunocore Holdings (IMCR) Stock Could Be 57.1% Undervalued After Annual Results
Immunocore Holdings (IMCR) continues to attract attention after reporting annual revenue of US$412.8 million and a net loss of US$27.6 million, which puts its current US$1.45b market value into sharper focus for investors. See our latest analysis for Immunocore Holdings. At a share price of US$28.59, Immunocore Holdings has seen its share price return decline 15.36% year to date, while the 1 year total shareholder return is down 9.81%. This points to cooling momentum after several years of...내러티브 업데이트 • Jun 06
IMCR: Future Upside Will Rely On High Risk Oncology Pipeline Progress
Narrative Update on Immunocore Holdings Analysts have reduced their price target for Immunocore Holdings to $33, down from $48. They cite a moderate total addressable market for Kimmtrak in uveal melanoma, expectations that sales are nearing peak, and a view that further upside depends on higher risk pipeline progress.내러티브 업데이트 • May 19
IMCR: Future Upside Will Depend On Risky Oncology Pipeline Execution
Analysts now set Immunocore Holdings' fair value at $34, up $1 from $33. This reflects adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E after recent Street research highlighted a more cautious view on upside without clearer pipeline progress.내러티브 업데이트 • Apr 25
IMCR: Pipeline Upside Will Rely On Higher Risk Oncology Programs
Analysts cut their price target on Immunocore Holdings to $33 from $48, noting that Kimmtrak provides an established revenue base in uveal melanoma. They indicated that the investment case now depends more on what they view as higher risk pipeline outcomes.내러티브 업데이트 • Apr 08
IMCR: Pipeline Risk And Sector Rotation Will Shape Balanced 2026 Outlook
Analysts have reset their average price target on Immunocore to $33. Some frame this move as a sign that Kimmtrak's uveal melanoma revenue potential is closer to peak, with future upside hinging more on higher risk pipeline assets, while others still see room for value in the broader small to mid cap biotech group.내러티브 업데이트 • Mar 24
IMCR: Sector Rotation And Pipeline Risk Will Shape Balanced 2026 Outlook
Narrative Update The analyst fair value estimate for Immunocore Holdings has shifted from $38 to $33. This change reflects mixed Street views, with some analysts highlighting Kimmtrak's moderate market and maturing sales, while others point to broader biotech sentiment and pipeline potential as key factors for future returns.내러티브 업데이트 • Mar 10
IMCR: Sector Rotation And Capital Production Shift Will Shape Bullish 2026 Outlook
Analysts have nudged their fair value estimate for Immunocore Holdings up from $37.00 to $38.00, citing higher Street price targets from $40 to $55. These targets reflect growing confidence in small to mid cap biotech as some companies are seen as shifting from capital consumers to capital producers and benefiting from improving sector sentiment.
내러티브 업데이트 • Feb 24
IMCR: Bullish View Will Center On 2026 Capital Producer Transition
Analysts have nudged their average price target on Immunocore higher, with recent moves such as a lift to $40 and an upgrade anchored by a new $55 target. These changes support a small upward adjustment in our modeled fair value to $66.57, alongside slightly higher discount rate and P/E assumptions.내러티브 업데이트 • Feb 08
IMCR: Sector Rotation And Pipeline Execution Will Shape Bullish 2026 Outlook
Narrative Update on Immunocore Holdings Analysts have lifted their average price target for Immunocore to a range anchored by the recent US$40 and US$55 targets. This reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples as they factor in improving sentiment toward small to mid cap biotech names.내러티브 업데이트 • Jan 24
IMCR: Balanced Outlook As Hepatitis B Data And Sector Rotation Shape 2026
Analysts have lifted their price target framework for Immunocore Holdings from about $24.93 to $37.00, reflecting recent Street research in which firms increased targets to as high as $55 and highlighted improving biotech fundamentals along with shifting investor attention toward small to mid cap commercial names. Analyst Commentary Recent Street research on Immunocore Holdings clusters around a common theme, with several firms linking their updated views to a broader shift in attention toward small to mid cap commercial biotech names.내러티브 업데이트 • Jan 10
IMCR: Bullish View Will Center On Advancing HBV TCR Bispecific Program
Narrative Update Analysts have lifted their blended price target for Immunocore, with recent moves such as a Morgan Stanley increase to $40 and a UBS move to $55 contributing to a higher implied fair value of about $66.36, based on updated assumptions for growth, margins and a higher future P/E multiple. Analyst Commentary Recent Street research around Immunocore centers on shifting views of small to mid cap biotech, updated price targets, and how investors might think about the balance between potential upside and execution risk.분석 기사 • Aug 02
Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jun 10
Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders have had their patience rewarded with a 27% share price jump in...Seeking Alpha • Apr 27
Immunocore Holdings: A Name On My Watch List
Summary Immunocore Holdings' shares have fallen over 60% since February 2024 due to lack of catalysts and competition for its main product, Kimmtrak. Kimmtrak, approved for metastatic uveal melanoma, faces market saturation and competition, but label expansion could significantly increase its market potential. Immunocore's pipeline includes promising early-stage oncology and infectious disease programs, but pivotal data for key trials won't be available until 2H26 or later. An analysis around Immuncore Holdings follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Apr 26
Improved Revenues Required Before Immunocore Holdings plc (NASDAQ:IMCR) Shares Find Their Feet
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 4.9x might make it look like a buy right...
새로운 내러티브 • Mar 23
AI Tools And Global Expansion Will Broaden KIMMTRAK's Market Reach
Expansion into less dense U.S. markets and international launches are key to driving revenue growth for Immunocore's KIMMTRAK.분석 기사 • Mar 04
Is Immunocore Holdings (NASDAQ:IMCR) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 27
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Summary Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks. IMCR's financials show increased product revenue and net income, with substantial cash reserves to support ongoing and future developments. Read the full article on Seeking Alpha분석 기사 • Jan 08
There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 5.2x might make it look like a strong buy...Seeking Alpha • Dec 10
Immunocore Is Adequately Valued, But Its Prospects Are Uncertain
Summary Immunocore's KIMMTRAK, targeting metastatic uveal melanoma, is FDA-approved and has shown significant clinical efficacy, with potential label expansions in cutaneous and adjuvant uveal melanoma. The company's ImmTAX platform develops TCR-based bispecific molecules, with ongoing trials for Tebentafusp and Brenetafusp in various cancers, showing promising early results. Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's strength and clarity. Despite recent stock declines and cautious market sentiment, future trial successes could make current prices attractive for conservative investors. Read the full article on Seeking Alpha분석 기사 • Oct 24
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Sep 19
Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry
Immunocore Holdings plc's ( NASDAQ:IMCR ) price-to-sales (or "P/S") ratio of 6.1x might make it look like a buy right...Seeking Alpha • Aug 12
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Summary Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V. I also believe IMCR could be a viable takeover target, given its diverse IP, growing revenues, and strong financials, which could potentially attract big pharma. Despite premium valuation risks, Immunocore's financials are robust, making it a "buy" for long-term investors familiar with biotech risks. Read the full article on Seeking Alpha분석 기사 • Jul 24
Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$58.75 Immunocore...분석 기사 • Jun 16
Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues
To the annoyance of some shareholders, Immunocore Holdings plc ( NASDAQ:IMCR ) shares are down a considerable 28% in...분석 기사 • May 11
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • May 11
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Immunocore Holdings plc ( NASDAQ:IMCR ) shareholders are probably feeling a little disappointed, since its shares fell...분석 기사 • Apr 05
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunocore Holdings fair value estimate is US$83.30 Immunocore...분석 기사 • Jan 22
Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Jan 21
Immunocore Holdings: Vulnerable To Profit Taking After Big Rally
Summary Immunocore Holdings plc is a commercial-stage biotechnology company focused on developing immunotherapies for cancer, infectious, and autoimmune diseases. The company's stock is up around 80% since late October and now is solidly in mid-cap territory. The stock has gotten shout outs from Barron's and Robert W. Baird to start the new year. Are further gains ahead in 2024 for Immunocore shareholders? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Dec 18
Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%
Immunocore Holdings plc ( NASDAQ:IMCR ) shares have had a really impressive month, gaining 37% after a shaky period...주주 수익률
| IMCR | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | 6.8% | 4.1% | 1.6% |
| 1Y | 0.3% | 41.1% | 18.6% |
수익률 대 산업: IMCR은 지난 1년 동안 41.1%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: IMCR은 지난 1년 동안 18.6%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| IMCR volatility | |
|---|---|
| IMCR Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: IMCR는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: IMCR의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1999 | 524 | Bahija Jallal | www.immunocore.com |
이뮤노코어 홀딩스는 자회사와 함께 미국, 유럽 및 전 세계에서 암, 전염병, 자가면역질환 환자를 위한 면역 조절 의약품의 개발 및 상용화에 종사하고 있습니다. 이 회사는 절제 불가능하거나 전이성 포도막 흑색종 치료를 위한 킴트락을 제공합니다. 또한 진행성 피부 흑색종 및 보조 포도막 흑색종 치료를 위한 임상 3상 시험 중인 테벤타펌프, 1차 진행성 피부 흑색종 치료를 위한 임상 3상 시험 중이며 다양한 종양 유형 치료를 위한 임상 1/2상 시험 중인 브레네타펌프 등 종양학 프로그램을 개발하고 있습니다; 대장암 등 진행성 고형암 치료를 위한 1/2상 임상시험 중인 IMC-R117C, PRAME을 발현하는 종양 환자를 대상으로 임상 1상 시험 중인 IMC-P115C.
Immunocore Holdings plc 기초 지표 요약
| IMCR 기초 통계 | |
|---|---|
| 시가총액 | US$1.65b |
| 순이익 (TTM) | -US$27.57m |
| 매출 (TTM) | US$412.81m |
4.0x
주가매출비율(P/S)-60.0x
주가수익비율(P/E)IMCR는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| IMCR 손익계산서 (TTM) | |
|---|---|
| 매출 | US$412.81m |
| 매출원가 | US$279.56m |
| 총이익 | US$133.25m |
| 기타 비용 | US$160.82m |
| 순이익 | -US$27.57m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.54 |
| 총이익률 | 32.28% |
| 순이익률 | -6.68% |
| 부채/자본 비율 | 100.0% |
IMCR의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/06 15:52 |
| 종가 | 2026/07/02 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Immunocore Holdings plc는 24명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jack Allen | Baird |
| William Maughan | Canaccord Genuity |
| Eric Schmidt | Cantor Fitzgerald & Co. |